{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+human+interleukin-2&page=4", "query": { "intervention": "Recombinant human interleukin-2", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 414, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+human+interleukin-2&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+human+interleukin-2&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T14:22:49.190Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000870", "title": "A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": null, "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2012-05-21", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000870" }, { "nct_id": "NCT00026312", "title": "Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Localized Resectable Neuroblastoma", "Localized Unresectable Neuroblastoma", "Recurrent Neuroblastoma", "Regional Neuroblastoma", "Stage 4 Neuroblastoma", "Stage 4S Neuroblastoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 1449, "start_date": "2001-10-26", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 172, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026312" }, { "nct_id": "NCT00045877", "title": "Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Recombinant Human Interleukin-2 and Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chiron Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2006-02-06", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 65, "location_summary": "Little Rock, Arkansas • Bakersfield, California • Fresno, California + 57 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045877" }, { "nct_id": "NCT01592045", "title": "ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "ch14.18 -NCI", "type": "BIOLOGICAL" }, { "name": "ch14.18-UTC", "type": "BIOLOGICAL" }, { "name": "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)", "type": "BIOLOGICAL" }, { "name": "Aldesleukin (IL-2)", "type": "BIOLOGICAL" }, { "name": "Isotretinoin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "8 Years", "sex": "ALL", "summary": "Up to 8 Years" }, "enrollment_count": 28, "start_date": "2012-08", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2015-09-23", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 13, "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01592045" }, { "nct_id": "NCT02417870", "title": "Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Anil K. Chandraker, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 2, "start_date": "2015-09", "completion_date": "2018-04", "has_results": true, "last_update_posted_date": "2021-06-24", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02417870" }, { "nct_id": "NCT00107354", "title": "Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": null, "start_date": "1998-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-09-20", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107354" }, { "nct_id": "NCT00001005", "title": "A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Zidovudine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": null, "completion_date": "1995-02", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001005" }, { "nct_id": "NCT03745326", "title": "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Cancer", "Pancreatic Cancer", "Gastric Cancer", "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL)", "type": "BIOLOGICAL" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Chest x-ray", "type": "DIAGNOSTIC_TEST" }, { "name": "Photography", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 5, "start_date": "2019-05-16", "completion_date": "2022-08-23", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03745326" }, { "nct_id": "NCT05883449", "title": "Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Hodgkin Lymphoma", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "AFM13", "type": "DRUG" }, { "name": "AB-101", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affimed GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-10-10", "completion_date": "2025-06-13", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05883449" }, { "nct_id": "NCT00052377", "title": "Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2002-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-06T14:22:49.190Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052377" } ] }